Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
about
HIV-Host Interactions: Implications for Vaccine DesignBroadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune SystemHumoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionModel-robust inference for continuous threshold regression models.Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controllerStructure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationAntibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and SubclassesLongitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants.Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs.Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionAntibody-virus co-evolution in HIV infection: paths for HIV vaccine development.Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission RiskHoles in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.The Role of Maternal HIV Envelope-Specific Antibodies and Mother-to-Child Transmission Risk.HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization.HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis.Neutralization tiers of HIV-1.Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment.Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.The Impact of IgG transplacental transfer on early life immunity
P2860
Q26765966-C27D3F35-9A92-42A5-A6D3-27799ED791DDQ33592852-47A90A5C-5522-4394-B5BF-277FF55516AAQ33620546-2AD7C3FF-9C64-4CCE-8DE8-254FE68A0309Q33699928-8D8920D8-6458-4648-930F-499F08E271C2Q33786447-7FCC9AFA-1778-4193-AFAA-0616464AAF5EQ34499013-A30EA337-D7B9-48D2-8EAD-3E23DF713042Q36081789-A3FC1BAE-A616-489B-923D-22D8FBE51DD5Q36118373-4451874E-9F53-4CD7-8178-458C97A92B00Q36246646-8C8E47FD-3107-49B6-8B54-011052090041Q36267348-29E66235-462E-445C-B78F-58307C633DEBQ37034798-22602C8B-93E8-492B-A712-74FE3204F470Q37359047-D8098666-7900-466F-BEA2-EB3DE8D9B5D4Q37363517-88FED217-5D80-48DF-A88B-51F7DF4DA783Q37363561-60754E86-DCA4-431D-8EE8-CD2DD7C3540DQ38977425-9145CB5E-04FD-4726-81A5-D2AF0F5CB840Q39108751-C279FC67-B501-4A26-90F6-6AD23102E705Q39108760-F30D80BE-AF8E-4954-AC94-03759286A8EEQ40178574-2F3872F9-8090-4F9B-A39F-F6A374A6805BQ40331385-32112029-13E6-4844-9C1C-B2BA21EAF0B9Q40568483-B34890C8-4EE3-416E-A396-9FB8FF529A68Q41471213-ADF13D26-6535-4312-AED0-EB278636C642Q41918753-BDAE164C-45B3-4A72-B47E-A5D955B7B60BQ47364595-0F9D1DF5-0CD4-4F59-8EB6-9AC97E999827Q47555844-85D74FD8-FBFA-495C-B3E3-6C47CBCA6DD1Q47562235-49B05203-081A-40DE-BC19-3BB97AAEA4C7Q50137034-5842A97E-4F38-40F2-BC1C-4457BC6287B2Q52570452-CAA8C253-122D-4DB2-A695-BBD4BEE865E8Q52577900-AE74D4F6-A613-4D83-8B04-6F59084BB6DDQ55359818-CE4FA167-0FB2-4F4B-9A80-DFA350A1AEEFQ56505186-F3B25C37-4D94-4CDA-9052-556AAAD7307D
P2860
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@ast
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@en
type
label
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@ast
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@en
prefLabel
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@ast
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@en
P2093
P2860
P50
P1433
P1476
Strain-Specific V3 and CD4 Bin ...... tralization-Resistant Viruses.
@en
P2093
Amit Kumar
Bhavna Hora
Dawn J Marshall
Georgia D Tomaras
Gift Kamanga
Hua-Xin Liao
John F Whitesides
Joseph G Sodroski
Joshua D Amos
P2860
P304
P356
10.1016/J.CHOM.2015.08.006
P50
P577
2015-09-01T00:00:00Z